dermatologyadvisor50m
Apremilast Enhances Outcomes in Early Oligoarticular PsA
In the phase 4 FOREMOST trial, treatment with apremilast improved both clinical and patient-reported outcomes at week 16 among patients with early oligoarticular PsA.
Too Old to Operate4h
Comparative Analysis of ILD in Patients With RA and PsA on Biologics
The following is a summary of “Interstitial Lung Disease in Patients With Rheumatoid Arthritis or Psoriatic Arthritis ...
Understanding Arthritis: Causes, symptoms, prevention, and treatment explained
Here are some strategies for potentially preventing arthritis: Maintain a Healthy Weight: Many cases of arthritis can be ...
BioSpace1d
Lilly’s Omvoh Beats J&J’s Stelara in Head-to-Head Phase III Crohn’s Disease Trial
At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...
Too Old to Operate1d
Impact of Ambulatory Care on ED Visits for IA
The following is a summary of “Deciding to Attend the Emergency Department: Experiences of Patients With Inflammatory ...
Managed Healthcare Executive1d
FDA Approves Imuldosa, the Fifth Stelara Biosimilar
Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.
rheumatologyadvisor1d
Patients With Rheumatoid Arthritis Frequently Have Persisting Pain
Patients with rheumatoid arthritis (RA) undergoing standard-of-care treatment frequently have persisting pain.
Pharmabiz1d
US FDA approves UCB’s 320 mg single-injection device presentations of Bimzelx
US FDA approves UCB’s 320 mg single-injection device presentations of Bimzelx: Brussels, Belgium Tuesday, October 15, 2024, 13:00 Hrs [IST] UCB, a global biopharmaceutical compa ...
Drug Store News1d
FDA approves Dong-A ST’s Stelara biosimilar
Imuldosa is a biosimilar to Stelara, a blockbuster drug developed by Janssen Biotech for the treatment of patients with ...
The American Journal of Managed Care1d
Navigating Racial Disparities in Psoriatic Arthritis: Insights from Patient-Reported Outcomes
Individuals with self-reported moderate to severe psoriatic arthritis (PsA) face a higher disease burden, particularly among ...
FDA Approves IMULDOSA (ustekinumab-srlf), Accord BioPharma's Biosimilar to STELARA (ustekinumab), for the Treatment of Chronic Inflammatory Conditions
PRNewswire Ahmedabad Gujarat [India] October 14 Accord BioPharma Inc the US specialty division of Intas Pharmaceuticals Ltd ...
HealthDay on MSN2d
Health Tip: Keep Psoriatic Arthritis Fatigue in Check
Fatigue is a common problem for people with psoriatic arthritis. According to the National Psoriasis Foundation, some studies indicate that half of all psoriatic arthritis patients have ...